Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 13/20 | 0.43 |
| ▸ | STK17B | O94768 | 1/20 | 0.41 |
| ▸ | STK17A | Q9UEE5 | 1/20 | 0.41 |
| ▸ | TTK | P33981 | 1/20 | 0.40 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 2/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.38 |
| ▸ | ACKR3 | P25106 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL624947 | 0.83 | FYN (0.51) | BRD4STK17BSTK17APIK3CG | |
| SCHEMBL626774 | 0.82 | PIK3CA (0.42) | BRD4STK17BSTK17ATTKPIK3CG | |
| SCHEMBL626603 | 0.77 | STK17B (0.45) | BRD4STK17BSTK17A | |
| SCHEMBL625400 | 0.76 | PIK3CA (0.43) | PIK3CG | |
| SCHEMBL625027 | 0.74 | CA12 (0.42) | STK17APIK3CGDYRK1A | |
| SCHEMBL626663 | 0.71 | BCHE (0.42) | BRD4STK17BSTK17AACKR3 | |
| SCHEMBL626602 | 0.69 | STK17B (0.47) | BRD4STK17BSTK17AACKR3 | |
| SCHEMBL1945374 | 0.68 | FYN (0.64) | PIK3CGMAPTTP53 | |
| SCHEMBL1944741 | 0.68 | FYN (0.47) | PIK3CG | |
| SCHEMBL15341063 | 0.66 | STK17B (0.51) | BRD4STK17BSTK17A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2012020215-A1 | AMINO- IMIDAZOLOTHIADIAZOLES FOR USE AS PROTEIN OR LIPID KINASE INHIBITORS | CENTRO NACIONAL DE INVESTIGACIONES ONCOLÓGICAS (CNIO) (ES) | 2012-02-16 | — | — | WO | disclosed |